TY - JOUR
T1 - A review of economic impact of targeted oral anticancer medications
AU - Shen, Chan
AU - Chien, Chun Ru
AU - Geynisman, Daniel M.
AU - Smieliauskas, Fabrice
AU - Shih, Ya Chen T.
N1 - Funding Information:
qualitative market research funded by the study sponsor. Recurrence rates were derived from the clinical trial publication of the ACOSOG Z9001 study. Costs were calculated from the published literature
PY - 2014/2
Y1 - 2014/2
N2 - There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.
AB - There has been a rapid increase in the use of targeted oral anticancer medications (OAMs) in the past decade. As OAMs are often expensive, economic consideration play a significant role in the decision to prescribe, receive or cover them. This paper performs a systematic review of costs or budgetary impact of targeted OAMs to better understand their economic impact on the healthcare system, patients as well as payers. We present our review in a summary table that describes the method and main findings, take into account multiple factors, such as country, analytical approach, cost type, study perspective, timeframe, data sources, study population and care setting when we interpret the results from different papers, and discuss the policy and clinical implications. Our review raises a concern regarding the role of sponsorship on findings of economic analyses as the vast majority of pharmaceutical company-sponsored studies reported cost advantages toward the sponsor's drugs.
UR - http://www.scopus.com/inward/record.url?scp=84893044810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893044810&partnerID=8YFLogxK
U2 - 10.1586/14737167.2014.868310
DO - 10.1586/14737167.2014.868310
M3 - Review article
C2 - 24378038
AN - SCOPUS:84893044810
SN - 1473-7167
VL - 14
SP - 45
EP - 69
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 1
ER -